Skip to main content
TOPICS
Videos
Provider
Payer
Pharma
Consumer
Investor
RESOURCES
Events
Jobs
Learning Center
Webinars
White Papers
REGIONS
ANZ
ASIA
EMEA
Global Edition
MORE
About
Advertise
Contact
Privacy Policy
ANZ
ASIA
EMEA
Global Edition
adult ADHD
Akili announces 27% growth of EndeavorRx prescriptions in Q2
By
Jessica Hagen
|
02:06 pm |
August 14, 2023
The company also announced its intentions to seek FDA approval for EndeavorOTC, its over-the-counter product for adults with ADHD.